Methoserpidine

Methoserpidine is used to treat hypertension (high blood pressure). Antihypertensive therapy seeks to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Methoserpidine is a medication used to treat severe nausea and vomiting caused by certain cancer drugs, including cisplatin and cyclophosphamide. It is also used to prevent nausea and vomiting that may occur during radiotherapy. Methoserpidine works by blocking the action of serotonin, a chemical in the brain that can cause nausea and vomiting. It is available as a tablet or injection and is taken before receiving chemotherapy or radiotherapy. Common side effects include drowsiness, dry mouth, and constipation.

Methoserpidine was previously explored as a potential medication, but its use has been discontinued due to safety concerns:

Brief History:

  • Developed in the 1960s: Initially introduced as an antihypertensive drug (medication to lower blood pressure).
  • Claimed advantage: Initially thought to be a potential alternative to reserpine (another antihypertensive drug) with fewer side effects, particularly the mental depression associated with reserpine.

Reasons for Discontinuation:

  • Limited effectiveness: Studies revealed that methoserpidine wasn't significantly more effective than other available antihypertensive medications at the time.
  • Similar side effects: Despite initial hopes, methoserpidine was later found to cause depression in a significant number of patients.
  • Availability of safer alternatives: The development of more effective and well-tolerated antihypertensive medications with fewer side effects rendered methoserpidine obsolete.

Current Status:

  • Not in clinical use: Methoserpidine is no longer prescribed due to the reasons mentioned above.
  • Not recommended: Healthcare professionals do not recommend using methoserpidine for any medical purpose.

Safer Alternatives:

A wide range of safe and effective antihypertensive medications are available today. Treatment choices are individualized by healthcare providers based on various factors, including:

  • Severity of high blood pressure
  • Underlying medical conditions
  • Individual patient characteristics and preferences
Anatomical Therapeutic Chemical Classification
C - Cardiovascular system
C02 Antihypertensives
C02A - Antiadrenergic agents, centrally acting
C02AA Rauvolfia alkaloids
Anatomical Therapeutic Chemical Classification
C - Cardiovascular system
C02 Antihypertensives
C02L - Antihypertensives and diuretics in combination
C02LA Rauwolfia alkaloids and diuretics in combination
External Links